Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 3 Clear all

Conditions: Colorectal Neoplasms
Interventions: 5-fluorouracil, bevacizumab, capecitabine, irinotecan, folinic acid, oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 45
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more

Conditions: Metabolic Syndrome X
Interventions: Endotoxin (LPS); Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Interventions: Placebo, Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Acute Appendicitis
Interventions: Piperacillin + Amoxicillin; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: aflibercept, High-dose aflibercept; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 84
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more

Conditions: Prostate Cancer
Interventions: Sipuleucel-T, APC-Placebo; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 65
States / cities: Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more

Conditions: Pain
Interventions: Hypertonic Saline, Normal Saline; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 4 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Large B-cell Lymphoma
Interventions: NT-I7, CAR T-cell therapy; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions: Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity; Drug · Procedure · Behavioral
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Lymphoma Leukemia
Interventions: allogeneic CAR19 regulatory T cells (CAR19-tTreg), Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis C, Chronic
Interventions: GS-6620, GS-6620 tablet, 450 mg BID, GS-6620 tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Anaheim, California • Los Angeles, California • DeLand, Florida + 8 more

Conditions: CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions: Clarithromycin XL, 2% Diltiazem; Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome
Interventions: Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Total-Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 4
States / cities: Oakland, California • Nashville, Tennessee • Seattle, Washington + 1 more

Conditions: Soft Tissue Sarcoma
Interventions: Gemcitabine, Docetaxel, Radiation, Surgical Resection, Blood draws; Drug · Radiation · Procedure + 1 more
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Kanglaite gelcap; Drug
Lead sponsor: KangLaiTe USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more

Conditions: Melanoma, Pancreatic Ductal Adenocarcinoma
Interventions: YH003, Toripalimab, Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Eucure (Beijing) Biopharma Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Dependence, in Remission
Interventions: AAV8-hCocH; Drug
Lead sponsor: W. Michael Hooten; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoma
Interventions: cilengitide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 3
States / cities: La Jolla, California • San Francisco, California • Nashville, Tennessee

Conditions: Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
Interventions: CATCH T cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2040
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alzheimer Disease, Down Syndrome
Interventions: ION269; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 35 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Indianapolis, Indiana • Kansas City, Kansas • Lexington, Kentucky + 2 more

Conditions: Alzheimer's Disease
Interventions: Placebo, Idalopirdine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 50 Years and older
Enrollment: 858 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more

Conditions: HIV Infection, HIV Infections
Interventions: SB-728-T; Genetic
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 6 more

Search by objective public record fields.

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer

Inflammation and the Metabolic Syndrome in Humans

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Hypertonic Saline as Therapy for Pediatric Concussion

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Ramipril for the Treatment of Oligospermia

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

AAV8-hCocH for Cocaine Use Disorder

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients